NANDROLONE PHENPROPIONATE


Trade Names	DURABOLIN NANDROLONE PHENPROPIONATE
Synonyms	Durabolin Nandrolone phenpropionate Nandrolone phenylpropionate Norandrostenolone phenylpropionate Nortestosterone furanpropionate Nortestosterone phenylpropionate
Status
Molecule Category	Free-form
UNII	KF7Z9K2T3W
EPA CompTox	DTXSID2023353
Parent Compound:	NANDROLONE


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	UBWXUGDQUBIEIZ-QNTYDACNSA-N
Smiles	C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@H]43)[C@@H]1CC[C@@H]2OC(=O)CCc1ccccc1
InChI	InChI=1S/C27H34O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h2-6,17,21-25H,7-16H2,1H3/t21-,22+,23+,24-,25-,27-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C27H34O3
Molecular Weight	406.57
AlogP	5.67
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	4.0
Polar Surface Area	43.37
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	30.0

Bioactivity

Mechanism of Action	Action	Reference
Androgen Receptor agonist	AGONIST	PubMed PubMed PubMed


Protein: Androgen Receptor Description: Androgen receptor Organism : Homo sapiens P10275 ENSG00000169083

Cross References

Resources	Reference
ChEBI	7468
ChEMBL	CHEMBL1200412
DrugBank	DB00984
DrugCentral	1882
FDA SRS	KF7Z9K2T3W
Human Metabolome Database	HMDB0015119
KEGG	C08155
PubChem	229455
SureChEMBL	SCHEMBL8443
ZINC	ZINC000003881613

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).